• Psyence BioMed began dosing patients in a Phase IIb trial of NPX-5, its natural psilocybin drug candidate, for adjustment disorder in cancer patients receiving palliative care.
• Trial results have not been presented; data are expected in the future as enrollment and dosing progress.
• Study aims to assess whether NPX-5 can ease psychological distress linked to adjustment disorder, with potential to support further clinical development if outcomes are favorable.
• Clinical site network in Australia expanded to five sites from three to support recruitment and shorten enrollment timelines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.